# F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

> **NCT05468294** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Philogen S.p.A.** · enrollment: 3 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** F16IL2
- **DRUG:** Nivolumab, fixed dose

## Key facts

- **NCT ID:** NCT05468294
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-09
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-07
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468294, "F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05468294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*